Quick Facts

Chemical Name
Thymalfasin
Also Known As
Zadaxin, Ta1
Category
Immune Support
Administration
Subcutaneous injection

What is Thymosin Alpha-1?

Thymosin Alpha-1 (Ta1) is a naturally occurring peptide first isolated from thymic tissue by Allan Goldstein in the 1970s. It plays a crucial role in immune system modulation and has been extensively studied for its ability to enhance immune responses. Ta1 is approved in numerous countries (but not the US) under the brand name Zadaxin for treating hepatitis B and C, and as an adjuvant therapy in cancer treatment.

How Does Thymosin Alpha-1 Work?

Thymosin Alpha-1 works by modulating the immune system at multiple levels. It enhances T-cell function, particularly helper T cells and cytotoxic T cells. It promotes dendritic cell maturation and antigen presentation, and stimulates the production of cytokines like interferon-gamma and interleukin-2. Ta1 also has direct effects on Toll-like receptors, enhancing innate immune responses. This broad immunomodulatory profile makes it valuable for both infectious diseases and cancer immunotherapy.

Research-Backed Benefits

Immune Enhancement

Strong Evidence

Boosts T-cell function and overall immune response.

Hepatitis Treatment

Strong Evidence

Approved in many countries for chronic hepatitis B and C.

Cancer Adjuvant

Moderate Evidence

Used alongside conventional cancer treatments to enhance immune response.

Vaccine Enhancement

Moderate Evidence

May improve response to vaccines in immunocompromised individuals.

Infection Resistance

Moderate Evidence

May help the body fight various infections more effectively.

Dosage Guidelines

Disclaimer: This content is for educational purposes only. Peptides are research compounds not approved by the FDA for human use. Always consult with a qualified healthcare provider.

Typical Range
1.6-6.4 mg per dose
Frequency
2-3 times weekly
Duration
6-12 months for chronic conditions

Standard approved dose for hepatitis is 1.6mg twice weekly. Higher doses used in cancer protocols.

Side Effects & Safety

  • Generally very well tolerated
  • Injection site reactions (rare)
  • Flu-like symptoms (uncommon)
  • Fatigue (rare)

Frequently Asked Questions

No, while approved in over 35 countries including Italy, China, and many others, Thymosin Alpha-1 is not FDA-approved in the United States.
It's used primarily for chronic hepatitis B and C treatment, and as an adjuvant in cancer immunotherapy. It's also studied for its general immune-enhancing properties.
Ta1 has an excellent safety record with decades of clinical use. Side effects are generally mild and uncommon.

References

  1. Romani L, et al. "Thymosin alpha 1 in infectious diseases." International Immunopharmacology, 2007. PMID: 17161332

Get the Complete Thymosin Alpha-1 Research Protocol

Join 50,000+ researchers with instant access to our comprehensive peptide resource.

Continue Your Research